Veritas In Silico Inc.

Veritas In Silico Inc. is a biotechnology firm focused on developing innovative low molecular weight drugs that target mRNA. The company harnesses artificial intelligence for drug discovery, aiming to enhance therapeutic solutions. Founded in 2016, Veritas In Silico Inc.

is headquartered in Tokyo, Japan. The company specializes in drug development, particularly targeting mRNA therapies. Shingo Nakamura serves as both the Founder and CEO, guiding the company through its strategic initiatives. Veritas In Silico has completed a total of 3 deals, with its most recent funding round—Series C—occurring on December 27, 2021, where it raised JPY 1.

4 billion (USD 10. 2 mn). This funding round included investors such as Global Brain and Mitsubishi UFJ Capital. The total amount raised by the company since its inception stands at JPY 1.

4 billion (USD 10. 2 mn), with a current company valuation of JPY 8090. 168 million (USD 58. 41 mn).

Veritas In Silico specializes in the development of low molecular weight drugs that target mRNA, employing a proprietary platform for drug discovery utilizing artificial intelligence and computational methods. Their focus includes addressing diseases through mRNA-targeted therapies and enhancing existing treatments. The company collaborates with prominent pharmaceutical firms such as Takeda Pharmaceutical and Shionogi, emphasizing its capacity to engage in partnerships that expand its research capabilities. Geographically, Veritas In Silico primarily operates in Japan while also establishing partnerships in the United States and Europe.

In the most recent fiscal year, Veritas In Silico reported revenue of JPY 540,571. 7 (USD 3. 91 mn), generated mainly through partnerships and collaborative agreements with large pharmaceutical companies. These agreements often include revenue structure based on milestone payments tied to specific project goals, leading to potential royalties upon successful commercialization of their therapeutic products.

Veritas In Silico plans to leverage its recent Series C funding of JPY 1. 4 billion (USD 10. 2 mn) to support the advancement of new mRNA-targeted products and expand into additional geographical markets, particularly in the United States and Europe, by 2023. The funding will facilitate research and development initiatives aimed at launching new therapies designed to enhance treatment options for challenging diseases.

This approach is expected to solidify their position in the biopharmaceutical landscape while fostering long-term growth.